UnitedHealth Q3 2026 earnings: the profit is recovering, the growth is still coming

UnitedHealth Group earned $4.69 per share in the third quarter of 2026 on an adjusted basis, up from $2.92 in the same quarter a year ago. That is a 61% increase. It is the number to hold onto if you own the stock, or a health care fund that leans on it.

Adjusted earnings leave out some items management considers outside the normal run of business. On GAAP terms, meaning the standard accounting rules every US listed company has to follow, earnings per share came in at $4.56, against $2.59 a year earlier. That is up 76%.

One quiet detail I like: the distance between those two measures narrowed. This quarter the adjustments added $0.13 per share. A year ago they added $0.33. When the company's preferred number and the strict number move closer together, there is less to explain away, and you can lean on the headline a bit more.

The quarter in one table

Revenue barely moved. Profit did most of the work.

Revenue of $112.7 billion was down 0.4% from $113.2 billion. For a company this size, that is flat. Operating income, the profit from running the business before interest and taxes, rose 52% to about $6.6 billion. That is roughly $2.2 billion more than a year ago, with no extra sales to show for it.

So the story of this quarter is not growth. It is repair.

Where the extra profit came from

The operating margin, meaning how much of each revenue dollar is left as operating profit, went from 3.8% to 5.8%. That is a gain of 2.0 points. The net margin, what is left after everything including tax, went from 2.1% to 3.6%, a gain of 1.5 points.

Those margins look thin because health insurers pass most of each premium straight through to doctors, hospitals and pharmacies. What matters is the direction, and this quarter it was clearly up.

Management pointed to several sources.

First, medical costs as a share of premiums improved. The industry calls this the medical care ratio: of every premium dollar collected, how much goes out the door paying for members' care. Lower is better for the insurer. UnitedHealth's ratio fell compared with last year. In management's telling, the company set its prices more carefully, kept a closer watch on medical bills and changed how some care gets delivered.

Second, Medicare Advantage is healing. These are private plans that seniors can choose instead of traditional government Medicare. Before 2026 began, the company reworked what its plans offer and where it sells them, choosing staying power over sheer size. Management now expects Medicare Advantage margins for 2026 to land near the top of its own target range, and put that down to the turnaround work of the past year, tighter control of medical spending and a plan lineup built to last.

Third, Optum Health, the arm that employs doctors and runs clinics, had what management called a strong quarter. It is returning to value-based care, where doctors are paid for keeping a group of patients healthy rather than per visit, and doing it with more discipline than before. One caution: management said this business normally dips in the fourth quarter, and it is spending extra on technology and clinician tools on top of that. Do not be surprised by a weaker final quarter from this segment.

Fourth, Medicaid, the state-funded coverage for lower-income families, is still losing a little money in its core business, but slightly less than the company had planned. Management called 2026 the bottom for those margins.

The guidance, and how to read it

UnitedHealth now expects full-year 2026 adjusted earnings of at least $20.50 per share, and GAAP earnings of $19.50 per share. The $1.00 gap between them reflects the same kind of items the adjusted figure leaves out, added up over a full year.

Two words in that guidance matter: "at least". A company that says that is telling you it sees the figure as a floor it is comfortable standing on. Management also said the guidance already accounts for the extra spending planned for the final months of the year.

More interesting for anyone holding the shares is what management said about next year. It called the 2026 figure a solid base to grow from, and said the lower end of its long-term earnings growth target is a reasonable starting point for 2027. It gave no number for 2027 itself, and promised a fuller outlook at an investor meeting before the end of the year. Even so, the chief executive said the team had already shared more about next year than it normally would at this stage.

When a company that has spent more than a year rebuilding trust starts talking about the following year in October, that says something about its confidence. Treat it as a signal, not a promise.

The parts still hurting

Not everything is fixed, and the call was fairly honest about that.

The commercial business, the coverage people get through their employers, is the weak spot. Medical cost trends there are running above what the company assumed at the start of the year, pushed by expensive specialty drugs and higher costs from clinicians. Management priced its 2027 plans on the assumption that those costs stay high, and said it will take longer than hoped to get commercial margins back to where they used to be.

A big irritant is the No Surprises Act, a federal law meant to protect patients from unexpected medical bills. The law includes an arbitration process for settling payment fights between insurers and out-of-network doctors. UnitedHealth says a small number of clinician groups and middlemen are using that process heavily and winning awards far above what Medicare would pay. So a law named No Surprises has become one of the bigger surprises on the insurer's cost line, which is a fine example of a name doing a lot of wishful thinking.

Medicaid depends on states raising the rates they pay, and those updates are arriving unevenly. That part is largely outside the company's control.

UnitedHealth has also been refining its Medicare plan footprint, scaling back some PPO plans, the kind that let members see doctors outside a set network, while still widening its overall reach. Whatever the reason for the flat top line, revenue will need fresh growth from somewhere to move.

What I'll watch next

The year-end investor meeting. This is where the 2027 outlook will appear. Whether management's hint about growth at the low end of its long-term range turns into an actual figure is the single most important item for the stock's next chapter.

Medicare enrollment. The annual enrollment period for seniors starts this week. UnitedHealth is aiming for growth in plans for people who qualify for both Medicare and Medicaid, plans for people with chronic conditions, and its high-value HMO plans, which keep members within a set network of doctors. Management said it would give formal membership guidance later this year. Growth there, at healthy margins, would show the repair turning into something more.

Star Ratings. These are government quality scores, out of five stars, that decide bonus payments for Medicare Advantage plans. Management said it improved on nearly every clinical and pharmacy measure this season, and expects most of its members to be in plans rated four stars or better over the next couple of years. More stars mean more money per member, so this is worth following even though it moves slowly.

Optum Rx. This is the company's pharmacy benefit manager, the middleman that negotiates drug prices for employers and health plans. For the first time, more than half of its members come from outside UnitedHealth's own insurance business, and client retention stayed high. That shows the business can win customers on its own merits, not just because it shares a parent with a big insurer.

Commercial costs. If specialty drug prices and arbitration awards keep climbing, the 2027 pricing could prove too light. This is the risk I would keep the closest eye on.

If you want to see how all of these pieces fit together in one place, with the businesses, the balance sheet and the valuation laid out side by side, our sample report shows what a full company report looks like.

What this means for you

If you own UnitedHealth, or a fund that holds a lot of it, this quarter tells you the company has stopped digging. Profit per share is up sharply, both margins have widened, and the gap between the company's preferred earnings measure and the strict accounting version has narrowed. That looks like real repair, and management calls the improvement durable. One quarter cannot prove that on its own.

What the quarter does not tell you yet is whether UnitedHealth can grow again. Revenue was flat, the employer business is still under pressure, and Medicaid hangs on state budgets. The next proof points are the 2027 outlook and the Medicare membership guidance, both promised before the end of the year.

The plain summary: the repair phase is well along, and the growth phase has not started. Knowing which of those two you are paying for is the most useful thing you can take from this quarter.

Sources: Unitedhealth Group's earnings release of 2026-10-13 (SEC filing), read 2026-10-14; Unitedhealth Group's earnings release of 2025-10-28 (Form 8-K exhibit 99.1), read 2026-07-02. The earnings call of 2026-10-13, in our own transcript. Changes, ratios and midpoints are my arithmetic on those figures.

Educational and proprietary. This explains what our research does, not the exact formula behind it, and it is not personalised investment advice. See the full disclaimer.